P-1075

P-1075
Clinical data
Other names	P1075
Drug class	ATP-sensitive potassium channel opener; Vasodilator; Antihypertensive agent
ATC code	None;
Identifiers
	IUPAC name 1-cyano-2-(2-methylbutan-2-yl)-3-pyridin-3-ylguanidine;
CAS Number	60559-98-0;
PubChem CID	43345;
ChemSpider	39498;
UNII	RA77IZ6B2F;
ChEBI	CHEBI:92004;
ChEMBL	ChEMBL11458;
CompTox Dashboard (EPA)	DTXSID60209335 ;
ECHA InfoCard	100.217.104
Chemical and physical data
Formula	C12H17N5
Molar mass	231.303 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(C)(C)N=C(NC#N)NC1=CN=CC=C1;
	InChI InChI=1S/C12H17N5/c1-4-12(2,3)17-11(15-9-13)16-10-6-5-7-14-8-10/h5-8H,4H2,1-3H3,(H2,15,16,17); Key:HKZNADVVGXKQDL-UHFFFAOYSA-N;

P-1075 is an ATP-sensitive potassium channel opener which was under development for the treatment of androgenic alopecia (pattern hair loss), arrhythmias, and ischemic heart disorders but was never marketed.^[1]^[2]^[3]^[4]^[5] It has been found to stimulate cultured hair follicles and to promote hair growth in balding stump-tailed macaques.^[3]^[4]^[5] The drug was being developed by AstraZeneca and LEO Pharma.^[1]^[2] It reached phase 2 clinical trials for alopecia and the preclinical research stage of development for arrhythmia and ischemic heart disorders prior to the discontinuation of its development by 2000.^[1]^[2] In terms of chemical structure, P-1075 is a guanidine derivative and a more potent analogue of pinacidil.^[3]

References

1 2 3 "P 1075". AdisInsight. 3 November 2000.
1 2 3 "Delving into the Latest Updates on P-1075 with Synapse". Synapse. 20 July 2025. Retrieved 24 July 2025.
1 2 3 Buhl AE, Conrad SJ, Waldon DJ, Brunden MN (July 1993). "Potassium channel conductance as a control mechanism in hair follicles". The Journal of Investigative Dermatology. 101 (1 Suppl): 148S–152S. doi:10.1111/1523-1747.ep12363290. PMID 8326149.
1 2 Messenger AG, Rundegren J (February 2004). "Minoxidil: mechanisms of action on hair growth". The British Journal of Dermatology. 150 (2): 186–194. doi:10.1111/j.1365-2133.2004.05785.x. PMID 14996087.
1 2 Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S (May 2012). "Minoxidil use in dermatology, side effects and recent patents". Recent Patents on Inflammation & Allergy Drug Discovery. 6 (2): 130–136. doi:10.2174/187221312800166859. PMID 22409453. Other potassium channel openers, like diazoxide [39, 40] and pinacidil [41] can cause hypertrichosis in humans as well as minoxidil. In balding macaques minoxidil, cromakalin and P-1075 (a pinacidil analogue) stimulate hair growth in about 20 weeks of topical treatment, whereas a fourth potassium channel opener, called RP49356, is not effective [42]. Harmon et al. suggested that minoxidil, diazoxide, cromakalin and pinacidil increased uptake of thymidine in hair growth cultures of mouse vibrissae follicles [43].

This dermatologic drug article is a stub. You can help Wikipedia by adding missing information.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by adding missing information.